文献速递消化系统肿瘤

一线转移性结直肠癌试验中同时性病变显著增加:一项系统综述的结果

Significant increase of synchronous disease in first-line metastatic colorectal cancer trials: Results of a systematic review.
PubMed 文献 · Eur J Cancer · 2016-11-05

该系统综述检索PubMed与EMBASE(2004年1月至2016年2月)中报告同时性与异时性转移的一线全身治疗或手术治疗转移性结直肠癌研究,纳入46篇文章(23项3期随机对照试验、20项队列研究、3项人群研究,共25,941例患者)。全身治疗随机对照试验中同时性转移比例随入组年份增加(rs .77,p < .001),估算中位总生存随时间略有改善(rs .48,p = .03),队列与人群研究未见显著趋势;共识别出17种同时性转移定义。

要点

  • 共纳入46篇文章,含23项3期随机对照试验、20项队列研究和3项人群研究,共25,941例患者。
  • 全身治疗随机对照试验中同时性转移比例随入组年份增加(rs .77,p < .001),估算中位总生存随时间略有改善(rs .48,p = .03)。
  • 共识别出17种同时性转移定义,作者认为统一定义与一致报告可改善跨研究比较。

核心结论

  • 在一线全身治疗随机对照试验中,近年入组的同时性转移性结直肠癌患者比例较异时性转移增加,这些试验总研究人群的估算中位总生存随时间略有改善。
  • 队列研究与人群研究中未观察到显著的纳入比例或生存趋势。
  • 共识别出17种同时性转移定义,作者认为统一定义与一致报告同时性与异时性转移比例可改善所有转移性结直肠癌研究的跨研究比较与数据解读。

研究设计与样本

  • 系统综述,检索PubMed与EMBASE(2004年1月至2016年2月)中研究一线全身治疗或手术治疗转移性结直肠癌、且包含同时性与异时性转移信息的研究。
  • 共纳入46篇文章,包括23项3期随机对照试验、20项队列研究和3项人群研究,合计25,941例患者。
  • 采用Spearman分析(rs)研究结局与研究中位入组年份之间的相关性。

主要发现

  • 全身治疗随机对照试验中,同时性转移性结直肠癌比例随入组年份增加(rs .77,p < .001)。
  • 全身治疗随机对照试验中,估算中位总生存随时间略有改善(rs .48,p = .03)。
  • 纳入的队列研究与人群研究中未观察到显著的纳入比例或生存趋势。
  • 共识别出17种不同的同时性转移性结直肠癌定义。

关键数值与推荐

  • 同时性转移性结直肠癌比例与入组年份的相关性:全身治疗随机对照试验中rs .77,p < .001。
  • 估算中位总生存与入组年份的相关性:全身治疗随机对照试验中rs .48,p = .03。
  • 共识别出17种同时性转移性结直肠癌定义。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although synchronous and metachronous metastases are considered as separate entities of metastatic colorectal cancer (mCRC) with different outcomes, its proportion is reported infrequently. We compared inclusion rates and survival of synchronous versus metachronous mCRC in different types of studies investigating initial systemic therapy or surgical treatment of mCRC. METHODS: We searched PubMed and EMBASE (January 2004 - February 2016) for mCRC studies investigating first-line systemic therapy or surgical treatment of mCRC including information on synchronous versus metachronous metastases. Outcomes were the proportion of synchronous mCRC, and estimated median overall survival (OS) of the total study population. Spearman analysis (rs) was used to study correlations between outcomes and median year of study enrolment. RESULTS: We included 46 articles, reporting data from 23 phase 3 randomised controlled trials (RCTs), twenty cohort and three population-based studies (total: 25,941 patients). Seventeen different definitions for synchronous mCRC were identified. In systemic therapy RCTs, we observed an increased proportion of synchronous mCRC during recent years (rs .77, p < .001). In these trials, estimated median OS slightly improved over time (rs .48, p = .03). No significant inclusion or survival trends were observed in included cohort and population-based studies. CONCLUSIONS: In recent years, the proportion of patients with synchronous compared with metachronous mCRC enrolled in first-line systemic therapy RCTs increased. Estimated median OS of the total study population in these RCTs slightly increased over time. Many different definitions of synchronous disease were used. Uniform definitions and consistent reporting of the proportion of synchronous versus metachronous metastases could improve cross-study comparisons and interpretation of reported data in all mCRC studies.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Goey KK, 't Lam-Boer J, de Wilt JH, et al. Significant increase of synchronous disease in first-line metastatic colorectal cancer trials: Results of a systematic review. Eur J Cancer. 2016. PMID: 27821320. doi:10.1016/j.ejca.2016.09.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。